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Background
Peanuts are one of the most common foods causing aller-
gic reactions in children. IgE-ab sensitization to peanut
has been reported in 7–11% of children in Western coun-
tries and the prevalence of peanut allergy (PA) in chil-
dren varies between 0.75% and 3%. Given the PA impact
on quality-of-life (QoL), accurate diagnosis is crucial
because many sensitized individuals are actually tolerant
to peanut. Peanut sensitization established by IgE antibo-
dies (IgE-ab) in blood or skin prick test (SPT) often
needs to be confirmed by the “gold standard” Double-
blind placebo-controlled food challenge (DBPCFC), a
risky and expensive procedure. In clinical practice an
open oral food challenge (OC) is performed instead of a
DBPCFC. PA can be effectively diagnosed using molecu-
lar allergology (MA), identifying subjects at risk for PA
reactions (IgE-ab to Ara h 1-2-3). No cost-effectiveness
(CE) analyses are available on MA for allergy.
Methods
Three 5-year Markov models simulate the flow of 200 chil-
dren PA suspected presenting to the general practitioner.
The models compare different diagnostic approaches
(DBPCFC, OC, SPT and MA), computing the cost-per-
QALY (Quality Adjusted Life Year) gained based on data
from the literature. Calculations were performed for
Sweden and BaseCase® was used to present results. Care
giver indirect costs are included in a sensitivity analysis.
Results
In Sweden, cost-per-QALY is 3.66 for SPT, 3.22 for
DBPCFC, 2.23 for OC and 4.34 for MA. The cost for
different diagnostic approaches is:
- SPT: 44851 SEK
- DBPCFC: 24278 SEK
- OC: 33031SEK
- MA: 11267 SEK
Conclusion
In Sweden, MA increases QoL, and it is associated with
reduced costs per patient with respect to the other strate-
gies. The hypothesized usage of MA could be a valid alter-
native and a useful diagnostic tool replacing the “gold
standard” DBPCFC in selected cases, DBPCFC still being
useful in subjects with conflicting immunological/clinical
results.
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